Selecting therapy for poor-risk advanced kidney cancer

In this video interview, Dr Earle Burgess from the Levine Cancer Centre in the USA talks about the factors that are considered when selecting therapy for patients with poor-risk advanced renal cell carcinoma (RCC).

Such factors include the risk status of the patient, burden or sites of disease, co-morbidities such as hypertension and cardiac disease, general fitness of the patient, method of administration of the treatment (oral versus intravenous), and side effect profile, particularly immune-related side effects.

Watch the video on Targeted Oncology here

In the following video, Dr Burgess discusses the use of TKIs for poor risk advanced RCC, in particular side effects and how to deal with them:

Watch the video on Targeted Oncology here

In the following video, Dr Burgess talks about selecting novel therapy, such as immunotherapy combinations, for the treatment of advanced RCC:

Watch the video on Targeted Oncology here

Share this Post!


Related post

  TOP